desisobutyrylciclesonide: an active metabolite of ciclesonide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6918281 |
| CHEMBL ID | 4594374 |
| SCHEMBL ID | 2984629 |
| MeSH ID | M0478411 |
| Synonym |
|---|
| desisobutyrylciclesonide |
| b-9207-021 |
| byk-20432 |
| des-cic |
| des-ciclesonide |
| desisobutyryl-ciclesonide |
| bdbm86696 |
| cic-ap |
| ciclesonide active principle |
| 161115-59-9 |
| unii-8dl7fh77sf |
| 8dl7fh77sf , |
| desisobutyryl ciclesonide |
| SCHEMBL2984629 |
| desisobuytyryl ciclesonide |
| cv7 , |
| J-009785 |
| HY-111490 |
| ciclesonide impurity b [ep impurity] |
| pregna-1,4-diene-3,20-dione, 16,17-(((r)-cyclohexylmethylene)bis(oxy))-11,21-dihydroxy-, (11.beta.,16.alpha.)- |
| (2'r)-2'-cyclohexyl-11beta,21-dihydroxy-16betah-[1,3]dioxolo[4',5':16,17]pregna-1,4-diene-3,20-dione |
| (11beta,16alpha)-16,17-[[(r)-cyclohexylmethylene]bis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione |
| (4ar,4bs,5s,6as,6bs,8r,9ar,10as,10bs)-8-cyclohexyl-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2h-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one |
| Q27458976 |
| cic-ap;ciclesonide active principle |
| (1s,2s,4r,6r,8s,9s,11s,12s,13r)-6-cyclohexyl-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one |
| pregna-1,4-diene-3,20-dione, 16,17-[[(r)-cyclohexylmethylene]bis(oxy)]-11,21-dihydroxy-, (11beta,16alpha)- |
| MS-28707 |
| ciclesonide-desisobutyryl |
| CHEMBL4594374 |
| DTXSID801043142 |
| AKOS040740768 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Freely circulating, protein unbound, active inhaled corticosteroid (ICS) can cause systemic adverse effects." | ( Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Chen, K; David, M; Guo, Z; Huang, Y; King, SP; Luo, Y; Nave, R; Rohatagi, S; Schemm, C; Shen, L, ) | 0.13 |
| " However, their long-term use is associated with various oropharyngeal and systemic side and adverse effects." | ( Ciclesonide: A Pro-Soft Drug Approach for Mitigation of Side Effects of Inhaled Corticosteroids. Derendorf, H; Mukker, JK; Singh, RSP, 2016) | 0.43 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The mean terminal half-life (t1/2) for des-CIC was also similar in patients with asthma (3." | ( Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar. Bethke, TD; Gunawardena, KA; Nave, R; Zech, K, 2006) | 0.33 |
| "After administration of a single dose of ciclesonide, the pharmacokinetic parameter estimates for des-CIC were equivalent between patients with mild-to-moderate asthma and healthy subjects, suggesting that there is comparable lung deposition and activation of ciclesonide in the 2 populations." | ( Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar. Bethke, TD; Gunawardena, KA; Nave, R; Zech, K, 2006) | 0.33 |
| " This pharmacokinetic drug-drug interaction study was conducted to confirm this major metabolic pathway in vivo by using the strong CYP3A4 inhibitor ketoconazole, and to assess the effect of ketoconazole on the pharmacokinetics of ciclesonide and des-CIC." | ( Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide. Böhmer, GM; Drollmann, A; Gleiter, CH; Nave, R, 2008) | 0.35 |
| "Fourteen healthy adults participated in this open-label, nonrandomized, fixed sequence, two-period, repeated-dose pharmacokinetic study." | ( Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide. Böhmer, GM; Drollmann, A; Gleiter, CH; Nave, R, 2008) | 0.35 |
| "For the parent compound, ciclesonide, no changes in the pharmacokinetic parameter estimates--the area under the serum concentration-time curve during the dosage interval (AUC(tau)), maximum serum concentration (C(max)) and time to reach the C(max)--were observed." | ( Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide. Böhmer, GM; Drollmann, A; Gleiter, CH; Nave, R, 2008) | 0.35 |
| " The availability of pharmacokinetic parameters (clearance [CL/F]; volume of distribution [Vd/F]; elimination half-life [T(½)]; and elimination rate constant [Kel]) in mice, rats, rabbits, and dogs enabled the prediction of human parameter values for des-ciclesonide using the well-accepted tool of allometry after intravenous administration of ciclesonide." | ( Allometric modeling of ciclesonide, a nonhalogenated glucocorticoid, and its active metabolite, desisobutyrylciclesonide, using animal-derived pharmacokinetic parameters. Ahlawat, P; Shaik, JB; Srinivas, NR, ) | 0.35 |
| " The unique pharmacokinetic and pharmacodynamic profile of ciclesonide offers a rationale that supports the favourable risk-benefit profile observed in clinical trials in patients with persistent asthma." | ( Clinical pharmacokinetic and pharmacodynamic profile of inhaled ciclesonide. Nave, R, 2009) | 0.35 |
| " The primary pharmacokinetic parameters were AUC(0-infinity) and C(max) of desisobutyryl ciclesonide." | ( Pharmacokinetics of ciclesonide and desisobutyryl ciclesonide after administration via aqueous nasal spray or hydrofluoroalkane nasal aerosol compared with orally inhaled ciclesonide: an open-label, single-dose, three-period crossover study in healthy vol Herzog, R; Laurent, A; Nave, R; Wingertzahn, MA, 2009) | 0.35 |
| " The method was fully validated and successfully applied to determine CIC and des-CIC simultaneously in human plasma and proved to be suitable for phase I clinical pharmacokinetic study of inhaled ciclesonide in healthy Chinese volunteers." | ( Simultaneous determination of ciclesonide and its active metabolite desisobutyryl-ciclesonide in human plasma by LC-APCI-MS/MS: application to pharmacokinetic study in healthy Chinese volunteers. Hang, TJ; Song, M; Su, MX; Wang, YQ; Zhuang, Y, 2011) | 0.37 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The pharmacokinetics of ciclesonide in all animal species were characterized by a low oral bioavailability (approximately 6% or less), a high clearance, and a large volume of distribution." | ( Ciclesonide disposition and metabolism: pharmacokinetics, metabolism, and excretion in the mouse, rat, rabbit, and dog. Cai, L; Chen, K; Gu, Z; Guo, Z; Howell, SR; Rohatagi, S; Stuhler, J; Wu, J, ) | 0.13 |
| " In conclusion, the data suggested that allometry tool may be amenable for the prediction of the pharmacokinetic parameters of des-ciclesonide despite differences in the conversion rates and bioavailability of the active metabolite in various animal species." | ( Allometric modeling of ciclesonide, a nonhalogenated glucocorticoid, and its active metabolite, desisobutyrylciclesonide, using animal-derived pharmacokinetic parameters. Ahlawat, P; Shaik, JB; Srinivas, NR, ) | 0.35 |
| " Ciclesonide is a corticosteroid with unique pharmacological profile including a high degree of serum protein binding, a low oral bioavailability and rapid systemic elimination." | ( Ciclesonide--a novel corticosteroid for the management of asthma. Bhandari, B; Chopra, D; Wardhan, N, 2012) | 0.38 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " A 1-compartment model with first-order absorption, an endogenous "predose" cortisol concentration at dose interval and a lag time based on a fixed, hypothetical cortisol dosing time of 10:00 PM could adequately characterize the circadian rhythm of endogenous cortisol release." | ( Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model. Krishnaswami, S; Pfister, M; Rohatagi, S; Sahasranaman, S, ) | 0.13 |
| "For the parent compound, ciclesonide, no changes in the pharmacokinetic parameter estimates--the area under the serum concentration-time curve during the dosage interval (AUC(tau)), maximum serum concentration (C(max)) and time to reach the C(max)--were observed." | ( Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide. Böhmer, GM; Drollmann, A; Gleiter, CH; Nave, R, 2008) | 0.35 |
| " The CIC showed the least serum cortisol suppression of the tested dosing regimens." | ( Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. Derendorf, H; Derom, E; Lahu, G; Nave, R; Xu, J, 2010) | 0.36 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1763051 | Cytotoxicity against African green monkey Vero E6 cells expressing TMPRSS2 assessed as reduction in cell viability at 20 uM incubated for 18 hrs by LDH assay | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Development of ciclesonide analogues that block SARS-CoV-2 RNA replication. |
| AID1763053 | Antiviral activity against SARS-CoV-2 JPN/TY/WK-251 infected in African green monkey Vero E6 cells expressing TMPRSS2 assessed as reduction in viral RNA replication by measuring replication copies assessed per well at 10 uM incubated for 18 hrs by qRT-PCR | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Development of ciclesonide analogues that block SARS-CoV-2 RNA replication. |
| AID1763054 | Antiviral activity against SARS-CoV-2 JPN/TY/WK-251 infected in African Green monkey Vero E6 cells expressing TMPRSS2 assessed as reduction in viral plaques incubated for 18 hrs by plaque reduction assay | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Development of ciclesonide analogues that block SARS-CoV-2 RNA replication. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (56.52) | 29.6817 |
| 2010's | 6 (26.09) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 8 (29.63%) | 5.53% |
| Reviews | 3 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (59.26%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||